These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 16601570

  • 1. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 2. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin inhibition in heart failure.
    McMurray JJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 26; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [Abstract] [Full Text] [Related]

  • 4. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 26; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 5. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May 26; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 6. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S, Wang D, Wilhelmsen L, Hennekens CH.
    Am Heart J; 2005 May 26; 149(5):939-43. PubMed ID: 15894981
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 26; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of the month. The CHARM study].
    Kulbertus H.
    Rev Med Liege; 2003 Oct 26; 58(10):646-52. PubMed ID: 14677527
    [Abstract] [Full Text] [Related]

  • 9. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R, Vanhaecke J, van Veldhuisen DJ, Ostergren J, Granger CB, Yusuf S, Pfeffer MA, Swedberg K.
    Eur Heart J; 2006 Jun 26; 27(12):1447-58. PubMed ID: 16754631
    [Abstract] [Full Text] [Related]

  • 10. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Jun 26; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 11. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS.
    J Hypertens Suppl; 2006 Mar 26; 24(1):S9-13. PubMed ID: 16601580
    [Abstract] [Full Text] [Related]

  • 12. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
    Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG, CHARM Investigators and Committees.
    Heart; 2007 Jan 26; 93(1):59-64. PubMed ID: 16952975
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 26; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 14. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
    Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S.
    J Card Fail; 1999 Sep 26; 5(3):276-82. PubMed ID: 10496201
    [Abstract] [Full Text] [Related]

  • 15. [Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].
    Umemoto S, Matsuzaki M.
    Nihon Rinsho; 2004 Jan 26; 62(1):211-8. PubMed ID: 14737855
    [Abstract] [Full Text] [Related]

  • 16. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR.
    Int J Clin Pract; 2005 May 26; 59(5):571-8. PubMed ID: 15857354
    [Abstract] [Full Text] [Related]

  • 17. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB, CHARM Investigators.
    Eur Heart J; 2008 Dec 26; 29(24):3022-8. PubMed ID: 18987098
    [Abstract] [Full Text] [Related]

  • 18. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S.
    Am Heart J; 2006 May 26; 151(5):985-91. PubMed ID: 16644318
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
    Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG, CHARM Investigators and Committees.
    Eur J Heart Fail; 2007 May 26; 9(5):510-7. PubMed ID: 17317308
    [Abstract] [Full Text] [Related]

  • 20. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees.
    Lancet; 2003 Sep 06; 362(9386):767-71. PubMed ID: 13678869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.